Feb 16, 2018
AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks
Feb 15, 2018
Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) Published in The Lancet
Jan 19, 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Jan 17, 2018
Bayer to Highlight New Research at ASCO GI 2018 Cancer Symposium
Dec 01, 2017
Roche Supports FDA Communication about Potential for Biotin Interference with Lab Tests
Oct 31, 2017
Blueprint Medicines Reports Third Quarter 2017 Financial Results
Sep 14, 2017
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
Sep 11, 2017
AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis
Sep 10, 2017
Lenvatinib Delays Deterioration in Certain Domains of Quality of Life in Patients with Unresectable Hepatocellular Carcinoma as Compared to Sorafenib in Phase 3 REFLECT Study
Sep 07, 2017
AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis
Sep 01, 2017
Global Allantoin Market - Analysis, Technologies & Forecasts to 2021 - Growing Use of Allantoin in Scar Treatment & in Tattoo Industry
Sep 01, 2017
Bayer to Highlight New Research at ESMO 2017 Congress
Aug 31, 2017
Eisai to Present New Clinical Data in Variety of Advanced Cancers at the ESMO 2017 Congress
Aug 28, 2017
Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial
Aug 22, 2017
Clinical and Regulatory Progress Boosting Biotech Sector
Jul 25, 2017
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings